OncoRay – National Center for Radiation Research in Oncology, Dresden

# Does RBE depend on LET and ion type?

A. Lühr, C. von Neubeck, M. Baumann, M. Krause, and W. Enghardt

16.09.2016, ENLIGHT meeting Utrecht





AND AND A CONTRACT AN


Universitätsklinikum Carl Gustav Carus



Deutsches Konsortium für Translationale Krebsforschung Partnerstandort Dresden

### Motivation – Challenges with RBE


- ConcoRay (2) Listan Reserve in Reserve in Reserve
- 1. Difficult to compare prescribed dose values in carbon ion therapy
- 2. RBE prescription/description differs between proton and ion therapy
- 3. Interdisciplinary task common communication



### Particle therapy



- 1. Improved dose distribution
- 2. Higher relative biological effectiveness (RBE)



### RBE – dependence on physics and biology



#### **RBE** depends on many factors, e.g.:

- Cell line

#### Physicsenergy


- Ion enpergy
- Ion/typend in vitro
- LET
- **Dod**point
- White classification of the second sec
- Dose
- Track structure

#### Biology

- Cell line
- In vivo and in vitro
- Endpoint
- Microenvironment



#### Linear energy transfer: LET



RBE for HSG cell lines, Furusawa et al. 2000


### RBE in vitro data – beam quality Q



### Beam quality: $Q = Z^2 / E$




#### E: kinetic energy of particle




RBE for HSG cell lines, Furusawa et al. 2000

### RBE in vitro data – beam quality Q






#### Dose distribution on the cellular level



ConcoRay Bitimat Center for Indicate Reserves in Orcelary Protein


#### Dose distribution on the cellular level: same beam quality



### Explanation – Track structure and LQ model








### LQ parameter $\alpha_p$ : dependence on Q



$$\alpha_p = \alpha + \beta m Q$$




In vitro  $\alpha_{o}$ /for/t/799, Foruls 3020, Etuals 3020, Balli 2000, M9998, Foruls 3020, 1996

### LQ parameter $\alpha_p$ : dependence on LET



$$\alpha_p = \alpha + \beta m LET$$




In vitro  $\alpha_{p}$  for HSG, Furusawa et al. 2000, Matsuura 2010



#### RBE as function of Q and $\alpha/\beta$


m = model parameter – fixed for all ions and cells; D<sub>t</sub> = threshold dose



RBE: about 120 in vitro RBE data points


### Conclusions

- RBE for same biological endpoint
  - Seems to **depend on Q = Z^2 / E** (beam quality)
  - Ion type, i.e., Z and LET may only be surrogates
- RBE and  $\alpha_p$  increase linearly with Q
  - Radial dose increases linearly with Q
- Impact on RBE description
  - separation between biology and physics
  - linearity in Q allows for dose averaging in an SOBP
  - *E* convenient quantity  $\rightarrow$  translation to treatment planning





Implication: Transfer C-ion RBE to proton therapy





#### **RBE depends on many factors, e.g.:**

#### Physics

- Ion energy
- Ion type
- LET
- Dose
- Track structure


#### Biology

- Cell line
- In vivo and in vitro
- Endpoint
- Microenvironment

## LQ parameter $\alpha_p$ : microenvironment




$$\alpha_p = \alpha + \beta m Q$$



 $\alpha_{\scriptscriptstyle D}$  for HSG cell lines, Furusawa et al. 2000




### Explanation – Track structure



UncoRay®

### RBE values for human cells: carbon






RBE for human cells, Review on LET dependence, Ando and Kase 2009



#### Variable RBE $\rightarrow$ inhomogeneous cell kill with tumor




Proton RBE for V79 and two SOBP, Wouters et al. 2015




#### Treat entire tumor volume with tolerance dose

#### → Not only distal part of SOBP




Proton RBE for glioma (U87) based on Chaudhary et al. 2014

Implication: Transfer C-ion RBE to proton therapy



### Spatial correlation: ion track and cell response






Cellular response to ion traversal, Niklas et al. 2013

### **Outlook: experimental verification**






OncoRay 2015

### Background



- RBE is considered *constant* in **proton therapy: RBE = 1.1**
- Experimental *in vitro* data show that this is not true
- No debate on variability of RBE for heavier ions, e.g., He- and C-ions



at different depths in SOBP

#### Why do we consider RBE differently for proton and ion therapy?


- a) Relevant physics/biology for protons systematically different.
- b) Better signal to noise ratio in RBE experiments with ions.

Proton in vitro survival data, glioma (U87): Chaudhary et al. 2014

### Particle therapy




#### **1. Improved dose distribution**



measured depth-dose curves, Dresden



#### 2. Higher relative biological effectiveness (RBE)



optimized depth-dose curves, treatment planning system TRiP